Atomoxetine for attention deficits in adults with mild HD [Huntington's disease]: a randomized, placebo-controlled crossover study

Trial Profile

Atomoxetine for attention deficits in adults with mild HD [Huntington's disease]: a randomized, placebo-controlled crossover study

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2010 Actual end date (1 Feb 2008) added as reported by ClinicalTrials.gov record.
    • 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
    • 31 Oct 2009 Results were published in the Journal of Clinical Psychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top